ReviewTranslational andrology and urology2026
Sodium-glucose cotransporter 2 inhibitors
Review in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Urolithiasis is a recurrent metabolic condition associated with obesity, metabolic syndrome, and type 2 diabetes (T2D), yet the relationship between modern antidiabetic drug classes and stone risk remains incompletely defined. This systematic review aimed to evaluate comparative clinical-event evidence on sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and dipeptidyl peptidase-4 inhibitor (DPP-4i) in relation to incident, recurrent, or severe urolithiasis outcomes. Methods: This systematic review (PROSPERO ID: CRD420261366483) was reported according to PRISMA 2020. The PICO framework was: (P) adults receiving antidiabetic pharmacotherapy; (I) SGLT2i use; (C) GLP-1 RA, DPP-4i, or other active antidiabetic therapies; and (O) incident, recurrent, or severe urolithiasis events. MEDLINE, Embase, Cochrane CENTRAL, and Scopus were searched from inception through April 2026, with additional studies identified through reference-list screening. Risk of bias was assessed using ROBINS-I. Findings were synthesized narratively. Results: Six comparative clinical-event studies met inclusion criteria. All were observational studies using active antidiabetic comparators. Across studies, SGLT2i use was consistently associated with lower urolithiasis risk compared with GLP-1 RA or DPP-4i Conclusions: SGLT2i use was consistently associated with lower incident, recurrent, and procedure-requiring urolithiasis risk
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.